Quectel Announces New Generation 5G Release 17 Module Series to Address Growing 5G FWA and eMBB Markets
27.2.2023 10:00:00 EET | Business Wire | Press release
MWC BARCELONA – Quectel Wireless Solutions, a global IoT solutions provider, today announces the launch of its latest generation 5G New Radio (NR) module series, the RG650E and RG650V, both of which follow the 3GPP Release 17 standard. These industrial grade 5G modules deliver enhanced performance in data rates, capacity, power saving, and latency as well as ultra-reliability, better addressing the growing 5G fixed wireless access (FWA), enhanced mobile broadband (eMBB), and industrial automation markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230226005190/en/
Quectel announces new generation 5G Release 17 module series to address growing 5G FWA and eMBB markets (Photo: Business Wire)
Based on the latest Snapdragon® X75 and X72 5G Modem-RF Systems from Qualcomm Technologies, Inc., the RG650E and RG650V series can work on both 5G non-standalone (NSA) and standalone (SA) modes. The RG650E supports a maximum bandwidth of 300 MHz in the sub-6GHz spectrum while the RG650V supports up to 200 MHz bandwidth. The adoption of Option 3x/ 3a/ 3 and Option 2 network architectures makes the modules backward compatible with global LTE and WCDMA networks.
Quectel also provides an RG650x-based System-on-Chip (SoC) solution with the latest Wi-Fi 7 technology, which significantly increases transfer speeds, reduces latency, and boosts overall network capacity for customer applications. Additionally, the module’s support of OpenWRT allows it to provide advanced networking features in a wider range of upstream ecosystem applications.
Integrated with a Quad-Core A55 processor, the RG650E and RG650V support 5G NR downlink carrier aggregation (CA), greatly improving data rates to meet the demand for super high data speeds in IoT verticals and applications, especially for FWA devices like CPE, home gateway, enterprise gateway, industrial router, mobile hotspot, eMBB terminals including high-definition live broadcast, AR/VR device, drone as well as industrial automation applications such as automated guided vehicles (AGV), remote control, and robot.
“We are excited to roll out the industry’s most advanced 5G NR modules based on the cutting-edge Snapdragon X75 and X72,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “Our latest 5G NR Release 17 modules feature unprecedented performance and significant advantages in communication capability. I believe they will provide an excellent Sub-6GHz, mmWave and Wi-Fi 7 solution for the growing 5G FWA and eMBB markets.”
“Snapdragon X75 and X72, the world’s first 5G Advanced-ready modem-RF system provides unparalleled features and capabilities for performance, power efficiency, and flexibility making it the ideal solution for various highly demanding applications and use cases,” said Gautam Sheoran, vice president, product management, Qualcomm Technologies, Inc. “We are excited to see Quectel adopting our new modem-RF systems to drive the next stage of 5G evolution in all key verticals including FWA, home getaways, Industrial IoT, and more.”
The RG650E and RG650V series supports Qualcomm® Location Suite with Qualcomm® GNSS HW Gen 9.v6 (Concurrent GPS, BeiDou, Galileo, GLONASS, NavIC, and QZSS). The integrated GNSS receiver greatly simplifies product design and provides quicker, more accurate, and more dependable positioning capability for applications in any environment. Additionally, they provide a wide range of interfaces such as USXGMII, PCIe, USB 2.0/ 3.0/ 3.1, PCM and supplementary functions including VoLTE and VoNR.
The Quectel 5G module offering is complemented by its range of antennas which help optimize connection efficiency and aid ease of installation of devices. These can be supplied pre-integrated with Quectel IoT modules to accelerate time to market and help eliminate commonly found integration issues.
Engineering samples of the RG650E and RG650V will be available for global markets in the first half of 2023. To learn more, visit the Quectel booth at MWC Barcelona 2023, Hall 5, Booth 5A20.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
Snapdragon and Qualcomm are trademarks or register trademarks of Qualcomm Incorporated.
Snapdragon and Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230226005190/en/
Contact information
Media:
Phil Rawcliffe, Head of Communications
phil.rawcliffe@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
